Bortezomib in mantle cell lymphoma. (April 2008)

• Record Type: Journal Article
• Authors: Suh, K Stephen; Goy, Andre
• Is Part Of: Future oncology. Volume 4:Number 2(2008)
• Page Start: 149
• Page End: 168
• Publication Date: 2008-04
• Subjects: bortezomib -- mantle cell lymphoma -- new anticancer agents -- proteasome inhibition; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/14796694.4.2.149
• Languages: English
• ISSNs: 1479-6694

Abstract

Mantle cell lymphoma (MCL) represents 6% of non-Hodgkin lymphomas, but is one of the most active fields of clinical investigation. Unfortunately, there is still no standard or curative therapy in MCL. Front-line therapy appears to benefit from intensification either through high-dose therapy with stem cell transplant consolidation or dose-intense chemotherapy with hyperfractionated cyclophosphamide, vincristine, adriamycin/doxorubicin and dexamethasone/rituximab. Most patients still relapse and a multitude of novel agents are currently being tested in this setting, including proteasome inhibitors with bortezomib (the first of its class and the first US FDA-approved drug for MCL), mTOR inhibitors, Bcl-2 inhibitors, antiangiogenesis agents and histone deacetylase inhibitors among others. An obvious effort is needed to enroll patients on clinical trials, the design of which might benefit from pharmacogenomics and a better understanding of MCL biology and its diversity.